Dermata Therapeutics Inc (DRMA) Stock Price, Quote & News

Company Profile

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 800 2543

Website: www.dermatarx.com

Address:

3525 Del Mar Heights Rd., Suite 332, San Diego, United States

_Sensei_ Sep. 17 at 7:31 PM

$DRMA going to get fun soon 📈

0 · Reply

JL_TradeZ Sep. 17 at 1:19 PM

The real edge comes from due diligence. Digging into filings, news flow, and market trends is like detective work. The reward is spotting a gem early or avoiding a dud before the market catches on. Sometimes it plays out, sometimes it doesn’t, but even on losses you know you did the work and made the right call. Funny how people love to copy ideas, but the moment they’re called out they get defensive and angry. In the end, the ones who do the real work always win. Real work pays off. Drop a like if you agree. $CDT $NUAI $DRMA $HOLO $EONR

0 · Reply

Molten_cpr Sep. 17 at 12:00 PM

$DRMA

0 · Reply

davidscr Sep. 17 at 8:39 AM

$DRMA How do you see it? Will this news make the stock go up?

1 · Reply

davidscr Sep. 17 at 8:38 AM

$DRMA Dermata Therapeutics Announces Presentation of Phase 3 Clinical Trial Results for XYNGARI™ at EADV Congress 2025. Dermata Therapeutics Announces Presentation of Phase 3 Clinical Trial Results for XYNGARI™ at EADV Congress 2025 Dermata Therapeutics Inc. has announced the upcoming presentation of an abstract from its Phase 3 clinical study, STAR-1, involving XYNGARI™ (DMT310) for treating moderate-to-severe acne. The abstract, titled "Once Weekly Topical Treatment with DMT310 Demonstrates Significant and Early Onset of Effect in Patients with Moderate to Severe Acne Vulgaris - Results from the STAR-1 Phase 3 Study," will be presented at the European Academy of Dermatology and Venereology Congress 2025. The congress will take place in Paris, France, from September 17-20, 2025. Full details of the abstract are scheduled for release on September 16, 2025

0 · Reply

makedatbread88 Sep. 16 at 9:39 PM

$QNRX wowww runner here next one to go is $DRMA 🤫 only 600k float

0 · Reply

ExecutiveEdge Sep. 16 at 6:37 PM

MSN is the kind of balance-sheet sleeper that can wake up violently. 📈 Book value is 80% higher 💸 88 months of cash 📊 Daily golden cross loading 📉 Still under $1 Once it gets attention, this won’t move slowly…. $CEI $WLDS $NAOV $LEXX $DRMA

0 · Reply

ExecutiveEdge Sep. 16 at 6:36 PM

0 · Reply

makedatbread88 Sep. 16 at 4:01 PM

$DRMA she’s ready to break out here folks adding all I can under $6.20 640k float can run hard here 🚀

0 · Reply

l33c14rky Sep. 16 at 3:57 PM

$DRMA

0 · Reply

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Sep 16, 2025, 8:35 AM EDT - 1 day ago

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Sep 10, 2025, 8:00 AM EDT - 7 days ago

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Aug 13, 2025, 5:00 PM EDT - 5 weeks ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 8, 2025, 8:00 AM EDT - 2 months ago

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

May 14, 2025, 9:00 AM EDT - 4 months ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 15, 2025, 8:30 AM EDT - 5 months ago

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Mar 27, 2025, 8:15 PM EDT - 6 months ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025, 10:21 AM EDT - 6 months ago

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Mar 27, 2025, 9:57 AM EDT - 6 months ago

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Mar 27, 2025, 8:00 AM EDT - 6 months ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 17, 2025, 4:16 PM EDT - 6 months ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Mar 4, 2025, 8:03 AM EST - 7 months ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Feb 25, 2025, 7:58 AM EST - 7 months ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jan 29, 2025, 4:05 PM EST - 8 months ago

Dermata to Present on BioPub on January 31, 2025

Jan 28, 2025, 4:05 PM EST - 8 months ago

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Jan 23, 2025, 4:15 PM EST - 8 months ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025, 8:00 AM EST - 8 months ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 21, 2025, 8:00 AM EST - 8 months ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dec 16, 2024, 9:00 AM EST - 9 months ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 10, 2024, 9:00 AM EST - 10 months ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 3, 2024, 9:00 AM EST - 10 months ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 13, 2024, 4:15 PM EST - 11 months ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 8:35 AM EST - 11 months ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Oct 8, 2024, 4:15 PM EDT - 1 year ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Sep 17, 2024, 5:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024, 9:00 PM EDT - 1 year ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

May 17, 2024, 8:30 AM EDT - 1 year ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

May 15, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Mar 27, 2024, 4:05 PM EDT - 1 year ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Feb 1, 2024, 9:00 AM EST - 1 year ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Jan 4, 2024, 4:05 PM EST - 1 year ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Dec 20, 2023, 4:05 PM EST - 1 year ago

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 16, 2023, 1:30 PM EST - 1 year ago

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 1 year ago

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Nov 9, 2023, 4:05 PM EST - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Aug 31, 2023, 9:00 AM EDT - 2 years ago

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Jun 27, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

Jun 13, 2023, 4:15 PM EDT - 2 years ago

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

Jun 8, 2023, 9:00 AM EDT - 2 years ago

Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results

May 26, 2023, 4:00 PM EDT - 2 years ago

Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

May 24, 2023, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

May 11, 2023, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

Apr 20, 2023, 6:00 AM EDT - 2 years ago

Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package

_Sensei_ Sep. 17 at 7:31 PM

$DRMA going to get fun soon 📈

0 · Reply

JL_TradeZ Sep. 17 at 1:19 PM

0 · Reply

Molten_cpr Sep. 17 at 12:00 PM

$DRMA

0 · Reply

davidscr Sep. 17 at 8:39 AM

$DRMA How do you see it? Will this news make the stock go up?

1 · Reply

davidscr Sep. 17 at 8:38 AM

0 · Reply

makedatbread88 Sep. 16 at 9:39 PM

$QNRX wowww runner here next one to go is $DRMA 🤫 only 600k float

0 · Reply

ExecutiveEdge Sep. 16 at 6:37 PM

0 · Reply

ExecutiveEdge Sep. 16 at 6:36 PM

0 · Reply

makedatbread88 Sep. 16 at 4:01 PM

$DRMA she’s ready to break out here folks adding all I can under $6.20 640k float can run hard here 🚀

0 · Reply

l33c14rky Sep. 16 at 3:57 PM

$DRMA

0 · Reply

BULLonROIDS Sep. 16 at 12:46 PM

RMCF stock can 3X huge volume pouring in and shorts are trapped on this micro floater. The company just reported record breaking financials and are expanding big time. Watching these too: $IQST $DRMA $FLUX $BTCT $FTHM ALL HAD NEWS this morning but not much of a move

0 · Reply

vcaelum Sep. 16 at 9:17 AM

$DRMA 550k float only, moves really thin, 52w low at $5 and current price at $5.5 CLEAN TICKER $FGI $CNFR $BGI $STKH

1 · Reply

JL_TradeZ Sep. 15 at 12:23 PM

🚨SPECIAL PLAY $DRMA is tight under a breakout spot after announcing a pivot into over-the-counter skin care last week. Add that to the Phase 3 trial win and new patent earlier this year, and you’ve got a fresh story with real catalysts. Only about half a million shares are in the float, and insiders own over a quarter of it. Cash per share is even higher than the stock price. If volume keeps building and it clears 6.45, this can move nicely PT: 7-9+ SL: 5.25

0 · Reply

etrade Sep. 15 at 12:06 PM

$HSDT $DRMA $NUWE $NAOV now who is the legend ;) next 100% gains on NAOV!

0 · Reply

etrade Sep. 15 at 10:47 AM

$HSDT $DRMA, $NUWE, $NAOV, look for symphaties ;)

0 · Reply

etrade Sep. 15 at 10:41 AM

$DRMA next ;)

1 · Reply

Pipelinepivots Sep. 14 at 4:45 AM

MITQ is giving early MCVT energy. No hype. No dilution. Golden cross lining up. Once volume hits this float it could rip 100–200% in a blink. Most won’t catch it in time…. $CRDL $CVKD $NAOV $AMST $DRMA

0 · Reply

MissionParabolics Sep. 12 at 10:29 PM

MITQ This could be the next parabolic runner, Already looking explosive this after hrs, imagine next week!🚨🚨 MITQ 💥 Small float/Known runner. 💥 NO Dilution 💥 Cash-Flow Positive 💥 golden cross forming on the daily!! 💥 High Insider Ownership $MGIH $SNTG $UK $DRMA

0 · Reply

LightningWolf_ Sep. 12 at 9:07 AM

$DRMA WATCHING

0 · Reply

Pipelinepivots Sep. 12 at 7:47 AM

MITQ looks just like $OCTO before it exploded: ✅ Golden cross forming ✅ Micro float ✅ Chart curled and holding ✅ Still completely under the radar All it takes is one catalyst and this goes vertical. $DRMA $TIVC $MODD $CRKN

0 · Reply

DonZulu Sep. 10 at 3:25 PM

$DRMA buying more this will be a banger next year . On radar

0 · Reply

Bubbasoup09 Sep. 10 at 12:42 PM

$DRMA 👀

0 · Reply

Market Cap	4.03M
Revenue (ttm)	0.00
Net Income (ttm)	-12.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	82,300
Avg Vol	30,470
Day's Range	N/A - N/A
Shares Out	682,000.00
Stochastic %K	46%
Beta	0.56
Analysts	Strong Sell
Price Target	$10.00